TNNI3 and hydrops fetalis: According to the results of a multivariate logistic regression analysis, a urinary hs-cTnI level > 4.1 pg/mL was associated with an increased risk of cardiovascular adverse events, such as AMI and HF, during a 3-month follow-up period.[141] Similarly, Streng et al utilized immunoprecipitation and a dual antibody-sandwich ELISA to detect urinary cTnI concentrations in patients with AMI.